Biliary stent LIFESTENT® and LIFESTENT® XL

Features: Longest lesion length indication (up to 240 mm) Unique helical design Engineered for bending, compression, torsion Dynamic vessel conformability Improved lesion coverage with a single stent A single-arm, prospective, non-randomized, multi-center study evaluating the safety and effectiveness of the LIFESTENT® SOLO™ in the treatment of symptomatic vascular disease of the SFA and/or proximal popliteal artery. Subjects were treated with conventional PTA followed by implantation of the Bard LIFESTENT® Vascular Stent. TRIAL OVERVIEW Q 76 patients Q 7 study sites in Germany Q Symptomatic de-novo or restenosed lesions Q Average lesion length of 91 mm *The LIFESTENT® Vascular Stent System and the LIFESTENT® SOLO™ Vascular Stent System are intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0-6.5 mm. † The LIFESTENT® 5 mm diameter was not included in the LIFESTENT® 200 mm Trial.